News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
BioSpace News Archive
Browse BioSpace’s published news and press releases by year, month, and day.
55 Results
Year
2005 (24679)
2006 (34770)
2007 (39687)
2008 (39410)
2009 (42118)
2010 (39616)
2011 (38383)
2012 (38416)
2013 (36268)
2014 (39673)
2015 (44433)
2016 (38330)
2017 (37191)
2018 (39124)
2019 (51338)
2020 (57666)
2021 (58724)
2022 (53928)
2023 (42568)
2024 (38486)
2025 (17740)
Month
January (4345)
February (4356)
March (4476)
April (4722)
May (4999)
June (4103)
July (3643)
August (3330)
September (4039)
October (5056)
November (4470)
December (3799)
Day
1 (7)
2 (15)
3 (243)
4 (292)
5 (235)
6 (83)
7 (4)
8 (20)
9 (229)
10 (249)
11 (163)
12 (210)
13 (72)
14 (2)
15 (29)
16 (196)
17 (228)
18 (224)
19 (189)
20 (95)
21 (7)
22 (4)
23 (193)
24 (210)
25 (262)
26 (241)
27 (78)
28 (20)
29 (55)
30 (184)
Year
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Month
January
February
March
April
May
June
July
August
September
October
November
December
Day
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
Job Trends
Clovis Oncology Highlights Rubraca® (rucaparib) Updated Data from the Ongoing TRITON2 Clinical Trial in Patients with mCRPC and Exploratory and Integrated Analyses in Recurrent Ovarian Cancer at the ESMO Congress 2019
43.9% confirmed objective response rate (ORR) in 57 RECIST*-evaluable patients with metastatic castration-resistant prostate cancer (mCRPC) and a BRCA1/2 mutation
September 29, 2019
·
18 min read
Drug Development
ImmunoGen Presents Initial Data from Phase 1b FORWARD II Triplet Cohort Evaluating Mirvetuximab Soravtansine in Combination with Carboplatin and Avastin® at ESMO
ImmunoGen, Inc. announced initial safety and overall response data from the Phase 1b FORWARD II triplet cohort evaluating mirvetuximab in combination with carboplatin and Avastin® in patients with recurrent, platinum-sensitive ovarian cancer at the European Society for Medical Oncology 2019 Congress in Barcelona, Spain.
September 29, 2019
·
5 min read
Biotech Bay
Late-Breaking Data Shows Abbott’s MitraClip™ is Cost Effective, Increases Life Expectancy and Improves Quality of Life
New late-breaking data at TCT 2019 demonstrate that Abbott’s MitraClip™ is cost-effective for heart failure patients with significant secondary mitral regurgitation compared to guideline-directed medical therapy alone
September 29, 2019
·
7 min read
Lilly Announces Positive Registrational Data for Selpercatinib (LOXO-292) in Heavily Pretreated RET-Altered Thyroid Cancers
Eli Lilly and Company presented data from the LIBRETTO-001 clinical trial intended to support the registration of oral selpercatinib1 monotherapy, also known as LOXO-292, for the treatment of RET-altered thyroid cancers.
September 29, 2019
·
8 min read
Drug Development
Isofol Announces Presentation on the Global Phase 3 Study of Arfolitixorin in Metastatic Colorectal Cancer at 2019 ESMO Congress
Isofol Medical AB, announced a poster presentation on the ongoing global Phase 3 AGENT clinical study in patients with metastatic colorectal cancer.
September 29, 2019
·
3 min read
Previous
6 of 6
